| 英文名稱 | Gracillin |
|---|---|
| 中文名稱 | 纖細(xì)薯蕷皂苷/纖細(xì)皂苷 |
| CAS號 | 19083-00-2 |
| 分子式 | C45H72O17 |
| 分子量 | 885.04 |
| 外觀 | |
| 熔點 | 290-293 °C |
| 酸度系數(shù)pKa | 12.78±0.70 | Condition: Most Acidic Temp: 25 °C |
| 英文名稱 | Gracillin |
|---|---|
| 中文名稱 | 纖細(xì)薯蕷皂苷/纖細(xì)皂苷 |
| CAS號 | 19083-00-2 |
| 分子式 | C45H72O17 |
| 分子量 | 885.04 |
| 外觀 | |
| 熔點 | 290-293 °C |
| 酸度系數(shù)pKa | 12.78±0.70 | Condition: Most Acidic Temp: 25 °C |
WKQ-0000594
中文名稱：纖細(xì)薯蕷皂苷
中文別名：纖細(xì)皂苷
英文名稱：Gracillin
英文別名：Gracillin (6CI,7CI,8CI);(3β,25R)-Spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-β-D-glucopyranoside;25(R)-Diosgenin 3-O-β-D-glucopyranosyl-(1→3)-[α-L-rhamnopyranosyl-(1→2)]-β-D-glucopyranoside;Diosgenin 3-O-(α-L-rhamnopyranosyl(1→2)-[β-D-glucopyranosyl(1→3)])-β-D-glucopyranoside;Diosgenin 3-O-β-gracillimatrioside;Dulcamarin C;Gracilline;Lilioglycoside G;NSC 698787;
分子式：C45H72O17
分子量：885.04
CAS號：19083-00-2
純度：HPLC≥98%
熔點：290-293 °C
密度：1.42±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
酸系度數(shù)：12.78±0.70 | Condition: Most Acidic Temp: 25 °C
儲存條件：-20℃，干燥、避光、密封
規(guī)格：5mg10mg20mg50mg100mg500mg1g2g等應(yīng)客戶需求包裝
供應(yīng)單位：四川省維克奇生物科技有限公司
供應(yīng)電話：028-81700200/4008005713
四川省維克奇生物科技有限公司生產(chǎn)中藥類標(biāo)準(zhǔn)品和天然植物有效單體，主打中藥對照品/標(biāo)準(zhǔn)品/天然植物有效單體，化學(xué)合成，抗生素三大板塊。公司推出丹參系列、龍膽系列、蟲草系列等，敬請關(guān)注！ 新批次有現(xiàn)貨，歡迎咨詢。
| In-situ growth of a spherical vinyl-functionalized covalent organic framework as stationary phase for capillary electrochromatography-mass spectrometry analysis | ||
| 來源：SCI：TALANTA | 作者：Wenqi Sun | 備注：影響因子：6.057 |
| 引用描述 | ||
Evodiamine, rutaecarpine, limonin were purchased from Chengdu herbpurify CO., Ltd (Chengdu, China). Polyphyllin VII, polyphyllin E and gracillin were obtained from Sichuan Weikeqi Biological Technology Co., Ltd (Chengdu, China). Carbamazepine and oxcarbazepine were bought from TCI Chemical Industry Development Co., Ltd (Shanghai, China). | ||
| Drug interaction study of natural steroids from herbs specifically toward human UDP-glucuronosyltransferase (UGT) 1A4 and their quantitative structure activity relationship (QSAR) analysis for prediction | ||
| 來源：SCI：PHARMACOLOGICAL RESEARCH | 作者：Min Xu | 備注：影響因子：4.816 |
| 引用描述 | ||
hecogenin (1), diosgenin (2), ruscogenin (3), gitogenin (4), tigogenin (5), solasodine (6), (24S,25S)-3β, 24-di-hydroxy-5α-spirostan (7), dracaenol C (8), 25(27)-dehydroruscogenin (9), (1β, 3β, 14α, 15α, 20R, 22S, 25R)-spirost-5-ene-tetrol (10), peimine (11), peiminine (12), peimisine (13), isoverticine (14), trillin (15), polyphyllin VI (16), polyphyllin VII (17), pallidifloside D (18), prosapogenin A (19), spongipregnoloside A (20), dioscin(21), solasonine (22), solamargine (23), gracillin (24), polyphyllin I(25), timosaponin BII (26), timosaponinA-III(27), ophiopogonin D (28), protobioside (29), (22S,25S)-26-O-β-d-glucopyranosyl-22,25-epoxyfurost-5-en-3β,26-diol-3-O-α-l-rha-mnopyranosyl(1 → 2)-β-d-gluc (30), pallidifloside E (31), parispseudoside (32), methylprotodioscin (33), protodioscin (34), pseudoprotodioscin (35), YS-IX (36), pallidifloside A (37), pallidifloside H (38), digoxin (39), bisdigoxigenin (40), 7β, 14α, 21-tri-hydroxy-diosgenin (41), 12β,14α,21-tri-hydroxy-diosgenin (42), and 11β,14α-di-hydroxyldiosgenin (43) were purchase from Sichuan weikeqi biotechnology company (Sichuan province, China). Pooled human liver microsomes (HLMs, 20 mg/mL) and pooled human primary hepatocytes were purchased from Rild Research Institute for LiverDiseases (Shanghai, China). | ||
